Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCFA2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $16,584.13 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Stelara 90 mg/ml syringes. The delivery order, issued on December 5, 2025, with an ultimate completion date of December 29, 2025, carries no set-aside designation, indicating DMS Pharmaceutical Group competed successfully in unrestricted federal procurement. This award flows from DMS Pharmaceutical Group's single-award Indefinite Delivery Contract under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring medical supply needs across Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group serves as a critical regional pharmaceutical supplier under the PPV-G GEN V framework, which was awarded on November 13, 2025, with a $500 million ceiling value and completion date of December 31, 2036. The company's established performance distributing a comprehensive range of pharmaceuticals—including branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals—to federal agencies positions it to fulfill the diverse pharmaceutical requirements of the military medical system. This delivery order for Stelara, an immunosuppressant biologic, exemplifies the company's role in supplying specialized therapeutic products essential to Department of Defense medical operations.
Quick answers
Who was awarded contract SPE2DR26FCFA2?
SPE2DR26FCFA2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 5, 2025.
How much is contract SPE2DR26FCFA2 worth?
The government has obligated $16,584 on SPE2DR26FCFA2.
Is contract SPE2DR26FCFA2 an order under another contract?
Yes. SPE2DR26FCFA2 is a delivery order under SPE2DR25D9130, an indefinite delivery contract.
Was contract SPE2DR26FCFA2 competed?
The extent of competition for SPE2DR26FCFA2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award